TAC-003 / Tallac Therap - LARVOL DELTA

TAC-003, a TLR9 agonist antibody conjugate for targeted immunotherapy of Nectin-4 expressing tumors (SITC 2023) - "TAC-003 shows a favorable safety profile in toxicity studies performed in cynomolgus monkeys. Conclusions The preclinical data presented here provides compelling rationale for further development of TAC-003 as an immunotherapy for Nectin-4-expressing solid tumors."

IO biomarker • Melanoma • Oncology • Solid Tumor • NECTIN4

Tallac Presents First Clinical Data for TAC-001 at SITC 2023 (Businesswire) - "...the Company presented preclinical data in the poster....that demonstrate TAC-003 induces robust immune cell activation, leading to innate and adaptive immunity against Nectin-4 positive cancers and potent single-agent anti-tumor activity. TAC-003 single agent treatment results in durable curative responses in models with a range of low to high Nectin-4 expression, including anti-PD-1 refractory tumors, with improved efficacy compared to enfortumab vedotin. TAC-003 has completed pre-clinical testing, including exploratory toxicological studies in cynomolgus monkeys, and has been selected as the Company’s third clinical candidate."

Preclinical • Oncology • Solid Tumor

Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Businesswire) - "Tallac Therapeutics...announced the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC 38th Annual Meeting in San Diego, CA, from November 3-5, 2023....Both abstracts will be available for viewing on October 31, 2023 at 9:00 am EDT on the Journal for Immunotherapy of Cancer (JITC) website."

P1/2 data • Preclinical • Solid Tumor

A Nectin-4 targeted TLR9 agonist antibody conjugate induces robust immune cell activation and anti-tumor responses (SITC 2022) - "Animals in which Nectin-4 TRAAC treatment led to tumor clearance were protected from tumor growth upon rechallenge, demonstrating that Nectin-4 TRAAC induces potent anti-tumor immunological memory. Conclusions The preclinical data shown here provide a strong rationale for pursuing Nectin-4 TRAAC for the treatment of Nectin-4-expressing solid tumors, including those that are refractory to CPI therapy."

IO biomarker • Melanoma • Oncology • Solid Tumor • NECTIN4